Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 112

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 112
---
 illustrative purposes only, an estimate of the 2024 remuneration package for the Company’s CEO and sole Executive Director under three performance scenarios, based on the remuneration policy set out above. The scenarios are defined as follows: Minimum (Fixed Pay Only)

| • | Salary (as of 1 March 2024: $765,000) |

| • | Benefits paid to 31 December 2024 ($21,904) |

| • | Pension (2.27% of salary (Maximum contribution $17,250 under Section 401(k))) |

Target

| • | Fixed pay as defined above |

| • | Target bonus (75% of salary) |

Maximum

| • | Fixed pay as defined above |

| • | Maximum bonus (150% of salary) |

The bar chart below does not include any value for equity-based award remuneration since the share price at the date the options were granted equals the options exercise price.

| (1) | No maximum with share price growth is disclosed, since the CEO’s remuneration package does not include any element of remuneration with performance measures or targets relating to more than one financial year. |

Executive Director Employment Agreement and Payments for Loss of Office The CEO, who is the only current Executive Director, is currently employed at-will pursuant to an employment agreement entered into with the Company’s indirect wholly owned subsidiary Immunocore LLC, effective as of

A-11

TABLE OF CONTENTS

5 February 2021. The CEO’s employment may be terminated by either party at any time for any or no reason, with or without notice. Severance payments no greater than those described in this policy will be payable to her on termination. Upon termination of the employment agreement, the CEO is required to resign from all other positions within the Group. Following termination of employment, the CEO will be bound by certain post-termination covenants. As is customary for US executives, the CEO’s remuneration is subject to a “best-after-tax” cutback for excise tax calculations under section 280G of the US Internal Revenue Code of 1986, with no tax gross-up. The CEO is also engaged as a director of the Company pursuant to an appointment letter dated 22 January 2021. The CEO is not entitled to any additional remuneration under this appointment letter. A copy of the contract and appointment letter may be viewed at the Company’s head office or may be requested from the Company Secretary at the AGM. The